Mary Kennedy

US Patent:

6652854, Nov 25, 2003

Filed:

Aug 3, 2001

Appl. No.:

09/921667

Inventors:

Kendall M. Mohler - Poulsbo WA
Dauphine S. Barone - Everett WA
Mary K. Kennedy - Seattle WA

Assignee:

Immunex Corporation - Seattle WA

International Classification:

A61K 3900

US Classification:

4241331, 4241541, 4241731, 514 12, 5303873, 5303887, 53038823

Abstract:

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF inhibitors.

US Patent:

7122183, Oct 17, 2006

Filed:

Aug 26, 2003

Appl. No.:

10/648136

Inventors:

Kendall M. Mohler - Seattle WA, US
Dauphine S. Barone - Seattle WA, US
Jacques J. Peschon - Seattle WA, US
Mary K. Kennedy - Seattle WA, US
John D. Pluenneke - Seattle WA, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

A61K 39/395
C07K 21/08
C07K 16/22

US Classification:

4241331, 4241541, 4241731, 5303873, 53038823

Abstract:

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.

US Patent:

7273609, Sep 25, 2007

Filed:

Aug 18, 2006

Appl. No.:

11/506645

Inventors:

Kendall M. Mohler - Poulsbo WA, US
Dauphine S. Barone - Mill Creek WA, US
Mary K. Kennedy - Seattle WA, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

A61K 39/395
C07K 21/08
C07K 16/22

US Classification:

4241331, 4241541, 4241731, 5303873, 53038823

Abstract:

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.

US Patent:

20080213259, Sep 4, 2008

Filed:

Aug 16, 2007

Appl. No.:

11/840136

Inventors:

Kendall M. Mohler - Poulsbo WA, US
Dauphine S. Barone - Mill Creek WA, US
Jacques J. Peschon - Seattle WA, US
Mary K. Kennedy - Seattle WA, US
John D. Pluenneke - Parkville MO, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

A61K 39/395
A61K 38/16
A01K 67/00
G01N 33/00
A61P 37/00
A61P 29/00

US Classification:

4241331, 4241301, 514 12, 4241581, 4241451, 800 9, 800 3

Abstract:

The invention provides methods of treating autoimmnune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.

US Patent:

20080299104, Dec 4, 2008

Filed:

May 23, 2008

Appl. No.:

12/126691

Inventors:

Mary B. Kennedy - Pasadena CA, US
Irene Knuesel - Zurich, CH
Jeong Oh - Thousand Oaks CA, US

International Classification:

A61K 38/45
A61K 38/00
A61K 31/7088
A61P 25/00

US Classification:

424 945, 514 2, 514 44

Abstract:

The invention provides methods of detecting and identifying agents which moduclate the expression or activity of synGAP, a brain-specific Ras/Rap GTPase activating protein. In vivo studies using knock-out and conditional knock-out transgenic animals show that the level of apoptosis in neurons correlates inversely with the level of synGAP protein, indicating that neuronal apoptosis is enhanced by reduction of synGAP. The invention also describes that synGAP is capable of modulating signal transduction pathways associated with the NMDA receptor and triggering apoptosis, including activation of Ras-GAP. Phosphorylation of synGAP by CaMKII increases its Ras GTPase-activating activity by about 70-95%. Moreover, when these and other phosphorylation sites in the synGAP carboxyl tail are mutated, stimulation of GAP activity after phosphorylation is reduced to about 215% as compared to about 70-95% for the wild type protein. Also, phosphosite-specific antibodies used to determine levels of synGAP phosphorylation are described herein.

US Patent:

20100071079, Mar 18, 2010

Filed:

Nov 10, 2009

Appl. No.:

12/615619

Inventors:

Kendall M. MOHLER - Poulsbo WA, US
Dauphine S. Barone - Mill Creek WA, US
Jacques J. Peschon - Seattle WA, US
Mary K. Kennedy - Seattle WA, US
John D. Pluenneke - Parkville MO, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

A61K 49/00
A61K 38/16
A61K 39/395
A01K 67/027
A61P 37/06
A61P 19/02

US Classification:

800 3, 4241301, 514 12, 4241331, 4241451, 4241581, 800 8, 800 9

Abstract:

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.